No quarterly revenue total was found in Seaport Therapeutics, Inc.'s SEC filings.
Seaport Therapeutics, Inc. (SPTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$22.7 million. As of Sep 30, 2026 it held $403.8 million in cash and investments and $4.7 million in total debt.
Revenue
—
Net income
$-26.39M
+57.8% vs prior quarter
Operating cash flow
$-22.68M
+13.2% vs prior quarter
Free cash flow
$-22.68M
+13.2% vs prior quarter
EPS
$-0.49
+72.5% vs prior quarter
Dividend per share
$0.00
Shares outstanding
53.53M
+0.0% vs prior quarter
Net cash
$399.11M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SPTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2042347
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
|---|---|---|---|
| Operating income | -$30.3M | -$65.8M | -$27.5M |
| Net income | -$26.4M | -$62.6M | -$25.4M |
| Diluted EPS | -$0.49 | -$1.78 | -$10.34 |
| Operating cash flow | -$22.7M | -$26.1M | -$20.2M |
| Free cash flow | -$22.7M | -$26.1M | -$20.2M |
| Total assets | $417.6M | $441.7M | $227.7M |
| Total liabilities | $20.2M | $19.1M | $18.0M |
| Stockholders' equity | $397.5M | $422.6M | -$115.6M |
| Cash and investments | $403.8M | $427.3M | $212.6M |
| Total debt | $4.7M | $5.0M | $5.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 2, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
| 10-Q | Quarterly report | Jun 8, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
Jun 8, 2026 | Jun 8, 2026 |
All 58 Seaport Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.